Acumen Pharmaceuticals, Inc. — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This annual filing reports full-year results, not a standalone fourth-quarter report. Acumen is a clinical-stage biopharmaceutical company with no approved products and no product-sales revenue. Its lead and only disclosed product candidate is ACU193, an investigational antibody for early Alzheimer’s disease.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $32.4 million | $12.3 million |
| General and administrative expense | $12.9 million | $7.3 million |
| Total operating expenses / operating loss | $45.2 million | $19.6 million |
| Net loss | $42.9 million | $100.6 million |
| Net loss per share, basic and diluted | $1.06 | $5.02 |
| Net cash used in operating activities | $35.2 million | $18.0 million |
Gross margin and operating margin are not meaningful because the company had no product revenue. The smaller 2022 net loss primarily reflects the absence of the $81.2 million 2021 expense from changes in the fair value of preferred-stock tranche and warrant liabilities; operating loss increased as development spending rose.
- Cash and cash equivalents: $130.1 million at year-end 2022.
- Marketable securities: $63.3 million at year-end 2022, versus $103.7 million at year-end 2021. Together with cash, these totaled approximately $193.4 million.
- Liquidity: Current assets were $180.3 million and current liabilities $7.8 million; reported working capital was $172.5 million. Management expected available cash and securities to fund operating and capital needs through 2025, subject to assumptions and spending needs.
- Debt: The filing does not report outstanding borrowings at year-end 2022. Total liabilities were $7.8 million, principally current operating and accrued obligations.
- Financing: The company raised $3.8 million net through its at-the-market offering in October 2022. Its shelf registration permits up to $200 million of securities offerings, including an ATM program of up to $50 million.
Material changes and business developments
- R&D expense increased $20.1 million, or 163%, year over year, mainly from clinical research organization costs, consulting, personnel, drug-safety testing and materials related to ACU193 development.
- G&A expense increased $5.6 million, or 77%, reflecting public-company costs and added financial and administrative infrastructure.
- Operating cash use increased to $35.2 million from $18.0 million. The company continued to rely on cash and securities rather than operating revenue to fund development.
- At December 31, 2022, total assets were $196.6 million, down from $230.3 million, and stockholders’ equity was $188.8 million, down from $225.2 million.
Outlook, risks and unusual items
- ACU193 is being studied in INTERCEPT-AD, a Phase 1, placebo-controlled trial in 65 people with early Alzheimer’s. Its primary focus is safety and immunogenicity; other measures include pharmacokinetics, cerebrospinal-fluid target engagement and exploratory cognitive and imaging assessments.
- After the reporting year, the company completed trial enrollment in February 2023 and anticipated topline results in the third quarter of 2023. In January 2023, it proposed changing Cohort 7 dosing from 60 mg/kg every two weeks to 25 mg/kg every two weeks, based partly on blinded preliminary pharmacokinetic data and two asymptomatic ARIA-E cases.
- The company received FDA Fast Track designation for ACU193 in October 2022. It planned to discuss a possible next-stage trial and registration pathway with the FDA after reviewing Phase 1 results. A Phase 2 trial, with or without expansion to Phase 3, would likely require additional financing to extend the cash runway into the second half of 2026.
- Management’s proposed treatment advantages—including selective targeting of amyloid-beta oligomers and potentially lower ARIA risk—are hypotheses supported by nonclinical findings, not established clinical benefits. ACU193 has not yet demonstrated efficacy in humans.
- Key risks include dependence on ACU193 as the sole product candidate; clinical and regulatory uncertainty; funding and potential dilution; reliance on contract manufacturers and research organizations; competition; intellectual-property protection; and reimbursement uncertainty. CMS coverage restrictions on accelerated-approval Alzheimer’s antibodies may affect the commercial environment.
- SVB event: Acumen reported approximately $1.8 million deposited at Silicon Valley Bank at year-end. Following the bank’s closure in March 2023, the company regained access to the full amount on March 14, 2023.
- The 2021 net loss included a substantial non-cash fair-value charge tied to preferred-stock financing instruments. The 2022 net loss should therefore be compared with operating loss and cash use as well as reported net loss.
Investor facts to verify
- Review final INTERCEPT-AD results, especially safety, ARIA cases, target engagement and whether exploratory cognitive findings support further development.
- Confirm the FDA’s response to the Cohort 7 protocol amendment and the timing, design and financing needs of the next clinical study.
- Monitor cash burn, investment maturities and any additional ATM or other capital raises against the stated runway through 2025.
- Assess whether clinical evidence supports the company’s proposed safety and efficacy differentiation from approved or competing Alzheimer’s therapies.
- Review the status and scope of ACU193 patent protection, including the disclosed patent portfolio’s projected 2031 expiry, and the costs and terms associated with manufacturing and licensing.
The financial statements were audited by Ernst & Young LLP, which issued an unqualified opinion. The auditor was not engaged to, and did not, express an opinion on internal control over financial reporting; management reported its controls effective at year-end 2022.